Feng-Hou Gao
Overview
Explore the profile of Feng-Hou Gao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
695
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Liu Z, Wang X, Wang H, Liu S, Zhang C, Liu F, et al.
Cancer Biol Ther
. 2024 Aug;
25(1):2385517.
PMID: 39087955
Background: CDK4 is highly expressed and associated with poor prognosis and decreased survival in advanced neuroblastoma (NB). Targeting CDK4 degradation presents a potentially promising therapeutic strategy compared to conventional CDK4...
2.
Yin S, Chen C, Liu Z, Liu S, Guo J, Zhang C, et al.
Cell Cycle
. 2023 May;
22(12):1407-1420.
PMID: 37202916
Isoalantolactone (Iso) is a bioactive lactone isolated from the root of Inula helenium L, which has been reported to have many pharmacological effects. To investigate the role and mechanism of...
3.
Zhang C, Zhang H, Liu S, Yang J, Gao F
Biochem Biophys Res Commun
. 2022 Aug;
627:5-11.
PMID: 36007335
CDK2 forms a complex with cyclin A and cyclin E to promote the progress of cell cycle, but when cyclin A and cyclin E are dissociated from the complex and...
4.
Guo J, Yin S, Liu H, Liu F, Gao F
Ann Transl Med
. 2021 Jun;
9(10):857.
PMID: 34164491
Background: The incidence of malignant melanoma accounts for only approximately 5% of skin malignant tumors, however, it accounts for 75% of its mortality. Long-chain non-coding RNA (lncRNA) has a wide...
5.
Lei H, Xu H, Shan H, Liu M, Lu Y, Fang Z, et al.
Nat Commun
. 2021 Jan;
12(1):51.
PMID: 33397955
Identifying novel drug targets to overcome resistance to tyrosine kinase inhibitors (TKIs) and eradicating leukemia stem/progenitor cells are required for the treatment of chronic myelogenous leukemia (CML). Here, we show...
6.
Yin S, Gao F
Front Immunol
. 2020 Aug;
11:1324.
PMID: 32765491
Tumor immune escape is an important part of tumorigenesis and development. Tumor cells can develop a variety of immunosuppressive mechanisms to combat tumor immunity. Exploring tumor cells that escape immune...
7.
Guo J, Fang H, Yang J, Liu S, Yao Q, Fan Y, et al.
Cell Biochem Funct
. 2020 Jul;
38(8):1100-1110.
PMID: 32627866
MicroRNAs can act as tumour suppressors or oncogenes by regulating cellular differentiation, proliferation and apoptosis, and the dysregulation of miRNA is involved in the occurrence and development of NSCLC. Here,...
8.
Zhu H, Zhang C, Guo Z, Yang J, Guo J, Chen C, et al.
Cancer Med
. 2019 Jul;
8(11):5313-5326.
PMID: 31339234
Oridonin could induce NB (neuroblastoma) cells growth inhibition by inducing apoptosis and cell cycle arrest, and the molecular mechanisms behind the effects deserve to be further explored. Here, oridonin was...
9.
Zhu H, Gao F
J Cancer
. 2019 Jul;
10(11):2488-2500.
PMID: 31258755
The BCR-ABL fusion protein with strong tyrosine kinase activity is one of the molecular biological bases of leukemia. Imatinib (Gleevec), a specific targeted drug for the treatment of chronic myeloid...
10.
Chen C, Gao F
Front Immunol
. 2019 Feb;
10:187.
PMID: 30800130
The progressive infiltration of immune cells is associated with the progression of melanoma. Specifically, Th17 cells in melanoma microenvironment have both antitumor and protumor effects. It is now necessary to...